Scripps Research Logo

The Burton Laboratory

Publications

Doores, K. J., Huber, M., Le, K. M., Wang, S. K., Doyle-Cooper, C., Cooper, A., Pantophlet, R., Wong, C. H., Nemazee, D. and Burton, D. R. 2012. 2G12-expressing B cell lines inform HIV carbohydrate vaccine design strategies. J. Virol. (In Press)

Benhnia, M. R., Maybeno, M., Blum, D., Aguilar-Sino, R., Matho, M., Meng, X., Head, S., Felgner, P. L., Zajonc, D. M., Koriazova, L., Kato, S., Burton, D. R., Xiang, Y., Crowe, J. E. Jr, Peters, B., and Crotty, S. 2012. Unusual features of vaccinia virus extracellular virion form (EV) neutralization resistance revealed in human antibody responses to the smallpox vaccine. J Virol. (In Press)

Hoot, S., McGuire, A. T., Cohen, K. W., Strong, R. K., Hangartner, L., Klein, F., Diskin, R., Scheid, J. F., Sather, D. N., Burton, D. R. and Stamatatos, L. 2013. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog 9:e1003106.

Moldt, B., Rakasz, E. G., Schultz, N., Chan-Hui, P. Y., Swiderek, K., Weisgrau, K. L., Piaskowski, S. M., Bergman, Z., Watkins, D. I., Poignard, P., Burton, D. R. 2012. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A. 109:18921-18925.

Ota, T., Doyle-Cooper, C., Cooper, A. B., Huber, M., Falkowska, E., Doores, K. J., Hangartner, L., Le, K., Sok, D., Jardine, J., Lifson, J., Wu, X., Mascola, J. R., Poignard, P., Binley, J. M., Chakrabarti, B. K., Schief, W. R., Wyatt, R. T., Burton, D. R., and Nemazee, D. 2012. Anti-HIV B Cell Lines as Candidate Vaccine Biosensors. J Immunol. 189:4816-4824.

Burton, D. R., Ahmed, R., Barouch, D. H., Butera, S. T., Crotty, S., Godzik, A., Kaufmann, D. E., McElrath, M. J., Nussenzweig, M. C., Pulendran, B., Scanlan, C. N., Schief, W. R., Silvestri, G., Streeck, H., Walker, B. D., Walker, L. M., Ward, A. B., Wilson, I. A., and Wyatt, R. 2012. A Blueprint for HIV Vaccine Discovery. Cell Host Microbe. 12:396-407.

Li, Q., L. Duan, M. Zeng, S. Pambuccian, L. Shang, A. Smith, S. Wietgrefe, P. J. Southern, C. S. Reilly, P. J. Skinner, M. L. Zupancic, J. V. Carlis, M. Piatak, Jr., D. Waterman, R. K. Reeves, K. Hammerman, J. Voss, D. R. Burton, J. D. Lifson, R. P. Johnson, and A. T. Haase. 2012. Vaccine-induced antibody concentrated at the mucosal border correlates with limited local and systemic SIV infection. Submitted.

Zhu, Z., S. O'Dell, G. Ofek, M. Pancera, X. Wu, B. Zhang, Z. Zhang, J. C. Mullikan, M. D. Simek, D. R. Burton, and et al. 2012. Somatic populations of PGT135-137 HIV-1-neutralizing antibodies identified by 454 pyrosequencing and bioinformatics. Front Microbiol. 3:315.

Burton, D. R., P. Poignard, R. L. Stanfield, and I. A. Wilson. 2012. Broadly neutralizing antibodies: new prospects to counter highly antigenically diverse viruses. Science 337:183-186.

Doria-Rose, N. A., I. Georgiev, S. O'Dell, G. Y. Chuang, R. P. Staupe, J. S. McLellan, J. Gorman, M. Pancera, M. Bonsignori, B. F. Haynes, D. R. Burton, W. C. Koff, P. D. Kwong, and J. R. Mascola. 2012. A Short Segment of the HIV-1 gp120 V1/V2 Region Is a Major Determinant of Resistance to V1/V2 Neutralizing Antibodies. J. Virol. 86:8319-8323.

Falkowska, E., A. Ramos, Y. Feng, T. Zhou, S. Moquin, L. M. Walker, X. Wu, M. S. Seaman, T. Wrin, P. D. Kwong, R. T. Wyatt, J. R. Mascola, P. Poignard, and D. R. Burton. 2012. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J. Virol. 86:4394-4403.

Giang, E., M. Dorner, J. C. Prentoe, M. Dreux, M. J. Evans, J. Bukh, C. M. Rice, A. Ploss, D. R. Burton, and M. Law. 2012. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 109:6205-6210.

Kong, L., E. Giang, J. B. Robbins, R. L. Stanfield, D. R. Burton, I. A. Wilson, and M. Law. 2012. Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc. Natl. Acad. Sci. U. S. A. 109:9499-9504.

Moldt, B., M. Shibata-Koyama, E. G. Rakasz, N. Schultz, Y. Kanda, D. C. Dunlop, S. L. Finstad, C. Jin, G. Landucci, M. D. Alpert, A. S. Dugast, P. W. Parren, F. Nimmerjahn, D. T. Evans, G. Alter, D. N. Forthal, J. E. Schmitz, S. Iida, P. Poignard, D. I. Watkins, A. J. Hessell, and D. R. Burton. 2012. A Nonfucosylated Variant of the anti-HIV-1 Monoclonal Antibody b12 Has Enhanced FcgammaRIIIa-Mediated Antiviral Activity In Vitro but Does Not Improve Protection against Mucosal SHIV Challenge in Macaques. J. Virol. 86:6189-6196.

Montero, M., N. Gulzar, K. A. Klaric, J. E. Donald, C. Lepik, S. Wu, S. Tsai, J. P. Julien, A. J. Hessell, S. Wang, S. Lu, D. R. Burton, E. F. Pai, W. F. Degrado, and J. K. Scott. 2012. Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane. J. Virol. 86:2930-2941.

Poignard, P., B. Moldt, K. Maloveste, N. Campos, W. C. Olson, E. Rakasz, D. I. Watkins, and D. R. Burton. 2012. Protection against High-Dose Highly Pathogenic Mucosal SIV Challenge at Very Low Serum Neutralizing Titers of the Antibody-Like Molecule CD4-IgG2. Plos One 7:e42209.

Ahmed, F. K., B. E. Clark, D. R. Burton, and R. Pantophlet. 2012. An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site. Vaccine 30:922-930.

Ackerman, M. E., B. Moldt, R. T. Wyatt, A. S. Dugast, E. McAndrew, S. Tsoukas, S. Jost, C. T. Berger, G. Sciaranghella, Q. Liu, D. J. Irvine, D. R. Burton, and G. Alter. 2011. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods 366:8-19.

Agrawal, N., D. P. Leaman, E. Rowcliffe, H. Kinkead, R. Nohria, J. Akagi, K. Bauer, S. X. Du, R. G. Whalen, D. R. Burton, and M. B. Zwick. 2011. Functional Stability of Unliganded Envelope Glycoprotein Spikes among Isolates of Human Immunodeficiency Virus Type 1 (HIV-1). Plos One 6:e21339.

Bonomelli, C., K. J. Doores, D. C. Dunlop, V. Thaney, R. A. Dwek, D. R. Burton, M. Crispin, and C. N. Scanlan. 2011. The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. Plos One 6:e23521.

Burton, D. R., A. J. Hessell, B. F. Keele, P. J. Klasse, T. A. Ketas, B. Moldt, D. C. Dunlop, P. Poignard, L. A. Doyle, L. Cavacini, R. S. Veazey, and J. P. Moore. 2011. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc Natl Acad Sci USA 108:11181-11186.

Chakrabarti, B. K., L. M. Walker, J. F. Guenaga, A. Ghobbeh, P. Poignard, D. R. Burton, and R. T. Wyatt. 2011. Direct antibody access to the HIV-1 MPER positively correlates with neutralization sensitivity. J Virol 85:8217-8226.

Dorner, M., J. A. Horwitz, J. B. Robbins, W. T. Barry, Q. Feng, K. Mu, C. T. Jones, J. W. Schoggins, M. T. Catanese, D. R. Burton, M. Law, C. M. Rice, and A. Ploss. 2011. A genetically humanized mouse model for hepatitis C virus infection. Nature 474:208-211.

Du, S. X., L. Xu, W. Zhang, S. Tang, R. I. Boenig, H. Chen, E. B. Mariano, M. B. Zwick, P. W. Parren, D. R. Burton, T. Wrin, C. J. Petropoulos, J. A. Ballantyne, M. Chambers, and R. G. Whalen. 2011. A Directed Molecular Evolution Approach to Improved Immunogenicity of the HIV-1 Envelope Glycoprotein. Plos One 6:e20927.

McLellan, J. S., M. Pancera, C. Carrico, J. Gorman, J. P. Julien, R. Khayat, R. Louder, R. Pejchal, M. Sastry, K. Dai, S. O'Dell, N. Patel, S. Shahzad-ul-Hussan, Y. Yang, B. Zhang, T. Zhou, J. Zhu, J. C. Boyington, G. Y. Chuang, D. Diwanji, I. Georgiev, Y. D. Kwon, D. Lee, M. K. Louder, S. Moquin, S. D. Schmidt, Z. Y. Yang, M. Bonsignori, J. A. Crump, S. H. Kapiga, N. E. Sam, B. F. Haynes, D. R. Burton, W. C. Koff, L. M. Walker, S. Phogat, R. Wyatt, J. Orwenyo, L. X. Wang, J. Arthos, C. A. Bewley, J. R. Mascola, G. J. Nabel, W. R. Schief, A. B. Ward, I. A. Wilson, and P. D. Kwong. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480:336-343.

Moldt, B., N. Schultz, D. C. Dunlop, M. D. Alpert, J. D. Harvey, D. T. Evans, P. Poignard, A. J. Hessell, and D. R. Burton. 2011. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for 2 FcγRs to define the role of effector functions in protection against HIV. J Virol 85:10572-10581.

Nicolaou, K. C., S. Sanchini, D. Sarlah, G. Lu, T. R. Wu, D. K. Nomura, B. F. Cravatt, B. Cubitt, J. C. de la Torre, A. J. Hessell, and D. R. Burton. 2011. Organic Synthesis toward Small-Molecule Probes and Drugs Special Feature: Design, synthesis, and biological evaluation of a biyouyanagin compound library. Proc Natl Acad Sci USA 108:6715-6720.

Pejchal, R., K. J. Doores, L. M. Walker, R. Khayat, P. Huang, S. K. Wang, R. L. Stanfield, A. Ramos, J. P. Julien, M. Crispin, R. Depetris, K. Y. Kang, U. Katpally, A. Marozsan, Y. Liu, R. McBride, C. Ogohara, J. Paulson, T. Feizi, C. N. Scanlan, C. H. Wong, J. P. Moore, W. C. Olson, A. B. Ward, W. R. Schief, P. Poignard, D. R. Burton, and I. A. Wilson. 2011. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334:1097-1103.

Scheid, J. F., H. Mouquet, B. Ueberheide, R. Diskin, F. Klein, T. Y. K. Olivera, J. Pietzsch, D. Fenyo, A. Abadir, K. Velinzon, A. Hurley, S. Myung, F. Boulad, P. Poignard, D. R. Burton, F. Pereyra, D. D. Ho, B. D. Walker, M. S. Seaman, P. J. Bjorkman, B. T. Chait, and M. C. Nussenzweig. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333:1633-1637.

Wahl-Jensen, V., S. Kurz, F. Feldmann, L. K. Buehler, J. Kindrachuk, V. DeFilippis, J. da Silva Correia, K. Fruh, J. H. Kuhn, D. R. Burton, and H. Feldmann. 2011. Ebola virion attachment and entry into human macrophages profoundly effects early cellular gene expression. PLoS Neglected Tropical Diseases 5:e1359.

Walker, L. M., M. Huber, K. J. Doores, E. Falkowska, R. Pejchal, J. P. Julien, S. K. Wang, A. Ramos, P. Y. C. Hui, J. L. Mitcham, P. H. Hammond, O. A. Olsen, P. Phung, S. Fling, C. H. Wong, S. Phogat, T. Wrin, M. D. Simek, P. G. P. Investigators, W. C. Koff, I. A. Wilson, D. R. Burton, and P. Poignard. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470.

Walker, L. M., D. Sok, Y. Nishimura, R. Pejchal, A. Ramos, M. D. Simek, Y. Geng, I. A. Wilson, P. Poignard, M. A. Martin, and D. R. Burton. 2011. Rapid development of glycan-specific, broad and potent anti-HIV-1 gp120 neutralizing antibodies in a SHIV- infected  macaque. Proc Natl Acad Sci USA 108:20125-20129.

Weinfurter, J. T., G. E. May, T. Soma, A. J. Hessell, E. J. Leon, C. E. Macnair, S. M. Piaskowski, K. Weisgrau, J. Furlott, N. J. Maness, J. Reed, N. A. Wilson, E. G. Rakasz, D. R. Burton, and T. C. Friedrich. 2011. Macaque long-term nonprogressors resist superinfection with multiple CD8+ T cell escape variants of simian immunodeficiency virus. J Virol 85:530-541.

Wu, X., T. Zhou, J. Zhu, B. Zhang, I. Georgiev, C. Wang, X. Chen, N. S. Longo, M. Louder, K. McKee, S. O’Dell, S. Perfetto, S. D. Schmidt, W. Shi, L. Wu, Y. Yang, Z. Y. Yang, Z. Yang, Z. Zhang, M. Bonsignori, J. A. Crump, S. H. Kapiga, S. E. Noel, B. F. Haynes, M. D. Simek, D. R. Burton, W. C. Koff, N. Doria-Rose, M. Connors, N. C. S. Program, J. C. Mullikin, G. J. Nabel, M. Roederer, L. Shapiro, P. D. Kwong, and J. R. Mascola. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by crystal structures and deep sequencing. Science 333:1593-1602.

Burton D. R. 2010. Scaffolding to build a rational vaccine design strategy. Proc Natl Acad Sci U S A. 107:17859-60.

Ng, C. T., Jaworski, J. P., Jayaraman, P., Sutton, W. F., Delio, P., Kuller, L., Anderson, D., Landucci, G., Richardson, B. A., Burton, D. R., Forthal, D. N., and Haigwood, N. L. 2010. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med 16:1117-9.

Astronomo, R. D., and D. R. Burton. 2010. Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov 9:308-24.

Astronomo, R. D., E. Kaltgrad, A. K. Udit, S. K. Wang, K. J. Doores, C. Y. Huang, R. Pantophlet, J. C. Paulson, C. H. Wong, M. G. Finn, and D. R. Burton. 2010. Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Chem Biol 17:357-70.

Burton, D. R., and R. A. Weiss. 2010. AIDS/HIV. A boost for HIV vaccine design. Science 329:770-3.

Doores, K. J., C. Bonomelli, D. J. Harvey, S. Vasiljevic, R. A. Dwek, D. R. Burton, M. Crispin, and C. N. Scanlan. 2010. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A 107:13800-5.

Doores, K. J., and D. R. Burton. 2010. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 84:10510-21.

Doores, K. J., Z. Fulton, V. Hong, M. K. Patel, C. N. Scanlan, M. R. Wormald, M. G. Finn, D. R. Burton, I. A. Wilson, and B. G. Davis. 2010. A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity. Proc Natl Acad Sci U S A.

Doores, K. J., Z. Fulton, M. Huber, I. A. Wilson, and D. R. Burton. 2010. Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged. J Virol 84:10690-9.

Gavrilyuk, J., H. Uehara, N. Otsubo, A. Hessell, D. R. Burton, and C. F. Barbas, 3rd. 2010. Potent Inhibition of HIV-1 Entry with a Chemically Programmed Antibody Aided by an Efficient Organocatalytic Synthesis. Chembiochem.

Hessell, A. J., E. G. Rakasz, D. M. Tehrani, M. Huber, K. L. Weisgrau, G. Landucci, D. N. Forthal, W. C. Koff, P. Poignard, D. I. Watkins, and D. R. Burton. 2010. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 84:1302-13.

Huber, M., K. M. Le, K. J. Doores, Z. Fulton, R. L. Stanfield, I. A. Wilson, and D. R. Burton. 2010. Very few substitutions in a germ line antibody are required to initiate significant domain exchange. J Virol 84:10700-7.

Pejchal, R., L. M. Walker, R. L. Stanfield, S. K. Phogat, W. C. Koff, P. Poignard, D. R. Burton, and I. A. Wilson. 2010. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A 107:11483-8.

Reynolds, M. R., A. M. Weiler, S. M. Piaskowski, H. L. Kolar, A. J. Hessell, M. Weiker, K. L. Weisgrau, E. J. Leon, W. E. Rogers, R. Makowsky, A. B. McDermott, R. Boyle, N. A. Wilson, D. B. Allison, D. R. Burton, W. C. Koff, and D. I. Watkins. 2010. Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge. J Virol 84:9190-9.

Scherer, E. M., D. P. Leaman, M. B. Zwick, A. J. McMichael, and D. R. Burton. 2010. Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc Natl Acad Sci U S A 107:1529-34.

Shedlock, D. J., M. A. Bailey, P. M. Popernack, J. M. Cunningham, D. R. Burton, and N. J. Sullivan. 2010. Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology 401:228-35.

Walker, L. M., and D. R. Burton. 2010. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 22:358-66.

Walker, L. M., M. D. Simek, F. Priddy, J. S. Gach, D. Wagner, M. B. Zwick, S. K. Phogat, P. Poignard, and D. R. Burton. 2010. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 6.

Burton, D. R., and P. Poignard. 2009. HIV: Immune memory downloaded. Nature 458:584-5.

Chen, L., Y. D. Kwon, T. Zhou, X. Wu, S. O'Dell, L. Cavacini, A. J. Hessell, M. Pancera, M. Tang, L. Xu, Z. Y. Yang, M. Y. Zhang, J. Arthos, D. R. Burton, D. S. Dimitrov, G. J. Nabel, M. R. Posner, J. Sodroski, R. Wyatt, J. R. Mascola, and P. D. Kwong. 2009. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326:1123-7.

Hessell, A. J., E. G. Rakasz, D. M. Tehrani, M. Huber, K. L. Weisgrau, G. Landucci, D. N. Forthal, W. C. Koff, P. Poignard, D. I. Watkins, and D. R. Burton. 2010. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 84:1302-13.

Lee, J. E., M. L. Fusco, D. M. Abelson, A. J. Hessell, D. R. Burton, and E. O. Saphire. 2009. Techniques and tactics used in determining the structure of the trimeric ebolavirus glycoprotein. Acta Crystallogr D Biol Crystallogr 65:1162-80.

Parren, P. W., and D. R. Burton. 2009. Immunology. Two-in-one designer antibodies. Science 323:1567-8.

Pejchal, R., J. S. Gach, F. M. Brunel, R. M. Cardoso, R. L. Stanfield, P. E. Dawson, D. R. Burton, M. B. Zwick, and I. A. Wilson. 2009. A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies. J Virol 83:8451-62.

Simek, M. D., W. Rida, F. H. Priddy, P. Pung, E. Carrow, D. S. Laufer, J. K. Lehrman, M. Boaz, T. Tarragona-Fiol, G. Miiro, J. Birungi, A. Pozniak, D. A. McPhee, O. Manigart, E. Karita, A. Inwoley, W. Jaoko, J. Dehovitz, L. G. Bekker, P. Pitisuttithum, R. Paris, L. M. Walker, P. Poignard, T. Wrin, P. E. Fast, D. R. Burton, and W. C. Koff. 2009. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 83:7337-48.

Stamatatos, L., L. Morris, D. R. Burton, and J. R. Mascola. 2009. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 15:866-70.

Walker, L. M., S. K. Phogat, P. Y. Chan-Hui, D. Wagner, P. Phung, J. L. Goss, T. Wrin, M. D. Simek, S. Fling, J. L. Mitcham, J. K. Lehrman, F. H. Priddy, O. A. Olsen, S. M. Frey, P. W. Hammond, S. Kaminsky, T. Zamb, M. Moyle, W. C. Koff, P. Poignard, and D. R. Burton. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-9.

Wu, L., T. Zhou, Z. Y. Yang, K. Svehla, S. O'Dell, M. K. Louder, L. Xu, J. R. Mascola, D. R. Burton, J. A. Hoxie, R. W. Doms, P. D. Kwong, and G. J. Nabel. 2009. Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain. J Virol 83:5077-86.

Walker LM, Bowley DR, Burton DR. Efficient recovery of high-affinity antibodies from a single-chain Fab yeast display library. J. Mol. Biol., 389: 365-75, 2009.

Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog., 5:e1000433, 2009.

Bowley DR, Jones TM, Burton DR, Lerner RA. Libraries against libraries for combinatorial selection of replicating antigen-antibody pairs. Proc. Natl. Acad. Sci. U S A., 106:1380-5, 2009.

Pantophlet R, Wang M, Aguilar-Sino RO, Burton DR. The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regions. J. Virol. 83:1649-59, 2009.

Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, Parren PW, Marx PA, Burton DR. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15:951-4, 2009.

Wang, S-K., P-H. Liang, R.D. Astronomo, T-L. Hsu, S-L. Hsieh, D.R. Burton , C-H. Wong .   Targeting the carbohydrates on HIV-1: interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN.    Proc. Natl. Acad. Sci. USA, 105 :3690-3695, 2008.

Bell, C.H., R. Pantophlet, A. Schiefner, L.A. Cavacini, R.L. Stanfield, D.R. Burton, I.A. Wilson.   Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization.   J. Mol. Biol ., 375 :969-78, 2008.

Astronomo, R.D., H-K. Lee, C.N. Scanlan, R. Pantophlet, C-Y Huang, I.A. Wilson, O. Blixt, R.A. Dwek, C-H. Wong, D.R. Burton .   A glycoconjugate antigen, based on the recognition motif of a broadly-neutralizing HIV antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the 'self' glycans of gp120 . J. Virol., 82: 6359-688, 2008.

Hedestam, G.B.K., R.A.M. Fouchier, S. Phogat, D.R. Burton , J. Sodroski, R.T. Wyatt.   The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.   Nature Rev. Microbiol., 6: 143-155, 2008.

Scanlan, C.N., D.R. Burton , R.A. Dwek, Making autoantibodies safe.   Proc. Natl. Acad. Sci. USA , 105 :4081-4082, 2008.

Walker, B.D., D.R. Burton .   Towards an AIDS vaccine.   Science, 320: 760-764, 2008.

Zhou, T., L. Xu, B. Dey, A.J. Hessell, D. Van Ryk, S-H. Xiang, X. Yang, M-Y. Zhang, M.B. Zwick, J. Arthos, D.R. Burton , D.S. Dimitrov, J. Sodroski, R. Wyatt, G.J. Nabel, P. D. Kwong.   Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature, 445 :732-737, 2007.

Nelson, J.D., F.M. Brunel, R. Jensen, E.T. Crooks, R.M.F. Cardoso, M. Wang, A. Hessell, I.A. Wilson, J.M. Binley, P.E. Dawson, D.R. Burton , M.B. Zwick.   In vitro affinity maturation of Z13, a broadly neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) gp41. J. Virol. 81:4033-4043, 2007.

Pantophlet, R., R.O. Aguilar-Sino, T. Wrin, L.A. Cavacini, D.R. Burton . Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Virology, 364: 441-453, 2007.

Dhillon, A.K., H. Donners, R. Pantophlet, W.E. Johnson, J.M. Decker, G.M. Shaw, F-H. Lee, D.D. Richman, R.W. Doms, G. Vanham, D.R. Burton .   Dissecting the neutralizing antibody specificities of broadly neutralizing sera from HIV-1 infected donors. J. Virol. , 81: 6548-6562, 2007.

Crooks, E.T., P.L. Moore, M. Franti, C.S. Cayanan, P. Zhu, P. Jiang, R. deVries, C. Wiley, I. Zharkikh, N. Sch ülke, K.H. Roux, D.C. Montefiori, D.R. Burton , J.M. Binley. A Comparative Immunogenicity Study of HIV-1 Virus-Like Particles Bearing Various Forms of Envelope Proteins, Particles Bearing no Envelope and soluble monomeric gp120.   Virology, 366 :245-262, 2007.

Braciale, T.J., Y.S. Hahn and D.R. Burton . Adaptive immune responses to viral infection.   In:   Fields Virology , (D.M. Knipe and P.M. Howley, Eds) Fifth Edition, Lippincott, pp. 279-325, 2007.

Law, M., R.M.F. Cardoso, I.A. Wilson, D.R. Burton . Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. J. Virol., 81: 4272-4285, 2007.

Oswald W.B., T.W. Geisbert, K.J. Davis, J.B. Geisbert, N.J. Sullivan, P.B. Jahrling, P.W.H.I. Parren, D.R. Burton .   Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys, PLoS Pathogens , 3 :62-66 2007.

Bowley, D.R., A.F. Labrijn, M.B. Zwick, D.R. Burton . Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage, Protein Engineering Design & Selection (PEDS) , 20: 81-90, 2007.

Scanlan, C.N., G.E. Ritchie, K. Baruah, D. Harvey, B.B. Singer, L. Lucka, M.D. Crispin, M.R. Wormald, P. Wentworth, Jr., N. Zitzmann, P.M. Rudd, D.R. Burton , R.A. Dwek.   Inhibition of mammalian glycan biosynthesis produces non-self antigens for a broadly neutralizing, HIV-1 specific antibody.   J. Mol. Biol. , 372 :16-22, 2007.

Mantis, N.J., A.J. Hessell, J. Palaia, S. Mahta, Z. Zhu, B. Corthesy, M.R. Neutra, D.R. Burton , E.N. Janoff.   Inhibition of HIV-1 infectivity and epithelial cell transfer by a recombinant human IgA to envelope gp120.   J. Immunology, 179: 3144-315 2 , 2007.

Hessell, A.J., L. Hangartner, M. Hunter, C.E.G. Havenith, F.J. Beurskens, J.M. Bakker, C.M.S. Lanigan, G. Landucci, D.N. Fothal, P.W.H.I. Parren, P.A. Marx, D.R. Burton .   The Fc receptor but not complement binding is important in antibody protection against HIV.   Nature , 449: 101-104, 2007.

Scherer, E.M., M.B. Zwick, L. Teyton, D.R. Burton . Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS , 21 :2131-2139, 2007.

Burton, D.R. , I.A. Wilson.   Square dancing antibodies.   Science , 317: 1507-1508, 2007.

Law, M., T. Maruyama, J. Lewis, E. Giang, A.W. Tarr, Z. Stamataki, P. Gastaminza, F.V. Chisari, I.M. Jones, R.I. Fox, J.K. Ball, J.A. McKeating, N.M. Kneteman, D.R. Burton .   Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.   Nature Medicine, 14: 26-27, 2007.

Zwick, M.B., Burton, D.R.   HIV-1 neutralization:   mechanisms and relevance to vaccine design.   Current HIV Research , 5 :608-624, 2007.

Koff, W.C., P.R. Johnson, D.I. Watkins, D.R. Burton , J.D. Lifson, K. Hasenkrug, A.B. McDermott, A. Schultz, T.J. Zamb, R. Boyle and R.C. Desrosiers.   HIV vaccine design:   Insights from live attenuated SIV vaccines. Nature Immunology , 7 :19-23, 2006.

Burton, D.R.   Images from the surface of HIV.   Nature , 441:817-818, 2006.

Burton, D.R. and R.A. Dwek. Sugar determines antibody activity.   Science , 313:627-628, 2006.

Delves, P.J., S.J. Martin, D.R. Burton , I.M. Roitt, Roitt's Essential Immunology, 11 th Edition, Blackwell Publishing, Oxford, U.K., In Press, 2006

Pantophlet, R., D.R. Burton .   gp120:   Target for neutralizing HIV-1 antibodies, Ann. Rev. of Immunol., 24 :739-769, 2006.

Law, M., P.P. Sanna, and D.R. Burton. Viral Subversion of Humoral Immune Responses.  In   Microbial Subversion of Immmunity: Current Topics ,   (P. J. Lachmann and M. B. A. Oldstone, Editors)  Caister Academic Press, Norfolk, UK, pp. 177-210, 2006.

Calarese, D., C. Scanlan, H-K. Lee, P. Rudd, C-H. Wong, R.A. Dwek, D.R. Burton , I. A. Wilson.   Towards a carbohydrate-based HIV-1 vaccine.   Carbohydrate Drug Design, American Chemical Society Symposium Series, Oxford University Press, Oxford, UK, 2006.

Koff, W.C., P.R. Johnson, D.I. Watkins, D.R. Burton , J.D. Lifson, K. Hasenkrug, A.B. McDermott, A. Schultz, T.J. Zamb, R. Boyle and R.C. Desrosiers.   HIV vaccine design:   Insights from live attenuated SIV vaccines. Nat. Immunol., 7 :19-23, 2006.

Moore, P.L., E.T. Crooks, M.L Porter, P. Zhu, C.S. Cayanan, M.B. Zwick, C. Wiley, P. Corcoran, M. Franti, J. Lifson, L.O. Arthur, L. Morris, K.H. Roux, D.R. Burton , and J.M. Binley.   Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.   J. Virol., 80:2515-2528, 2006.

Selvarajah, S. B. Puffer, F-H. Li, P. Zhu, Y Li, R. Wyatt, K. Roux, R. Doms and D.R. Burton .   Focused dampening of antibody responses to the immunodominant variable loops by engineered soluble gp140.    AIDS Research & Human Retroviruses , 24: 1-14, 2008.

Burton, D.R., R.L. Stanfield, I.A. Wilson.   Antibody vs. HIV in a clash of evolutionary titans, Proc. Natl. Acad. Sci. , 102: 14943-14948, 2005.

Lindenbach, B.D., M.J. Evans, A.J. Syder, B. Wolk, T.L. Tellinghuisen, C.C. Liu, T. Maruyama, R.O. Hynes, D.R. Burton, J.A. McKeating, C.M. Rice.   Complete replication of hepatitis C virus in cell culture.   Science , 309:623-626, 2005.

Cardoso, R.M.F., M.B. Zwick, R.L. Stanfield, R. Kunert, J.M. Binley, H. Katinger, D.R. Burton, I.A. Wilson.   Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41:   Implications for vaccine design.   Immunity , 22 :163-173, 2005.

Calarese, D. H-K. Lee, C-Y Huang, M. Best, R. Astronomo, R. Stanfield, H. Katinger, D.R. Burton , C-H Wong and I. Wilson.   Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12 by chemical synthesis and structural analysis.   Proc. Natl. Acad. Sci., 102:13372-13377 2005

Zhong, J., P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D.R. Burton , S.F. Wieland, S.L. Uprichard, T. Wakita F. V. Chisari.   Robust hepatitis C virus infection in vitro.   Proc. Natl. Acad. Sci., 102 :9294-9299, 2005.

Zwick, M.B., R. Jensen, S. Church, M. Wang, G. Stiegler, R. Kunert, H. Katinger, D.R. Burton . The anti-human immunodeficiency virus type 1 antibodies 2F5 and 4E10 require only a surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol., 79 :1252-1261 , 2005.

Zwick, M.B., H.K. Komori, R.L. Stanfield, S. Church, M. Wang, P.W.H.I. Parren, R. Kunert, H. Katinger, I.A. Wilson and D.R. Burton .   The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-HIV-1 antibody 2F5.   J. Virol., 78: 3155-3161, 2004.

Burton, D.R. , R.C. Desrosiers, R.W. Doms, W.P. Koff, P.D. Kwong, J.P. Moore, G.P. Nabel, J. Sodroski, I.A. Wilson and R.P. Wyatt.   HIV vaccine design and the neutralizing antibody problem. Nature Immunology , 5 :233-236, 2004.

Binley, J.M., T. Wrin, B. Korber, M.B. Zwick, M. Wang, C. Chappey, G. Stiegler, R. Kunert, S. Zolla-Pazner, H. Katinger, C.J. Petropoulos, D.R. Burton .   A comprehensive cross-clade neutralization analysis of panel of anti-HIV-1 monoclonal antibodies.   J. Virol., 78: 13232-13252 , 2004.

Burton, D.R. , R.C. Desrosiers, R.W. Doms, M.B. Feinberg, R.C. Gallo, M. Hahn, J.A. Hoxie, E. Hunter, B. Korber, A. Landay, M.M. Lederman, J. Lieberman, J.M. McCune, J.P. Moore, N. Nathanson, L. Picker, D. Richman, C. Rinaldo, M. Stevenson, D.I. Watkins, S.M. Wolinsky, J.A. Zack.   A sound rationale needed for phase III HIV-1 vaccine trials.   Science, 303 :316, 2004.

Pantophlet, R., I. Wilson and D.R. Burton .   Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. Protein Engineering, Design and Selection , 17: 749-758, 2004.

Moore, J.P., D.R. Burton .   Urgently needed:   a flter for the HIV-1 vaccine pipeline.   Nature Medicine, 10: 769-771, 2004.

Zwick, M.B., R.A. Williamson, D.R. Burton .   Combinatorial phage antibody libraries.     Encyclopedia of Molecular Cell Biology & Molecular Medicine (R.A. Meyers, Editor) Wiley-VCH Verlag, Weinheim, Germany, Vol. 3, pp. 75-99, 2004.

Zwick, M.B., E.O. Saphire and D.R. Burton .   gp41:   The shy protein of HIV.   Nature Medicine , 10:133-134, 2004.

Woof, J.M., D.R. Burton .   Human antibody-Fc receptor interactions illuminated by crystal structures, Nat. Rev. Immunol., 4:89-99, 2004.

Pantophlet, R., I. A. Wilson and D.R. Burton .   Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J. Virol., 77 :5889-5901, 2003.

Calarese, D.A., C.N. Scanlan, M.B. Zwick, S. Deechongkit, Y. Mimura, R. Kunert, P. Zhu, M.R. Wormald, R.L. Stanfield, K.H. Roux, J.W. Kelly, P.M. Rudd, R.A. Dwek, H. Katinger, D.R. Burton * and I.A. Wilson*.   Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science , 300 :2065-2071, 2003.

Pantophlet, R., D.R. Burton .   Immunofocusing:   antigen engineering to promote the induction of HIV-neutralizing antibodies.   Trends in Molecular Medicine, 9:468-473, 2003.

Binley, J.M., C.S Cayanan, C. Wiley, N. Schulke, W.C. Olson and D.R. Burton .   Redox-triggered Infection by disulfide-shackled HIV-1 pseudovirions. J. Virol. , 77 :5678-5684, 2003.

Poignard*, P., M. Moulard, E. Golez, V. Vivona, M. Franti, S. Venturini, M. Wang, P.W.H.I. Parren and D.R. Burton *.   Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies.   J. Virol., 77: 353-365, 2003.

Labrijn, A.F., P. Poignard, A. Raja, M.B. Zwick, K. Delgado, M. Franti, J. Binley, V. Vivona, C. Grundner, C-C. Huang, M. Venturi, C.J. Petropoulos, T. Wrin, D.S. Dimitrov, J. Robinson, P. Kwong, R.T. Wyatt, J. Sodroski and D.R. Burton. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary HIV-1. J. Virol ., 77:10557-10565, 2003.

Burton, D.R. Antibodies, viruses and vaccines. Nature Reviews, Immunology. 2:706-713, 2002.

Scanlan, C.N. R. Pantophlet, M.R. Wormald, E.O. Saphire, R. Stanfield, I.A. Wilson, H. Katinger, R.A. Dwek, P.M. Rudd and D.R. Burton, The broadly neutralizing anti-HIV-1 antibody 2G12 recognizes a cluster of a1Æ2 mannose residues on the outer face of GP120, J. Virol., 76:7306-7321, 2002.

Parren, P.W.H.I., T.W. Geisbert, T. Maruyama, P.B. Jahrling and D. R. Burton. Pre and Post-Exposure Prophylaxis of Ebola Virus Infection in an Animal Model by Passive Transfer of a Neutralizing Human Antibody. J. Virol., 76:6408-6412, 2002.

Binley, J.M., R.W. Sanders, A. Master, C.S. Cayanan, C.L. Wiley, L. Schiffner, B. Travis, S. Kuhmann, D.R. Burton, S-L. Hu, W.C. Olson, J.P. Moore. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol., 76:2606-2616, 2002.

E.O. Saphire, R.L. Stanfield, M.D.M. Crispin, P.W.H.I. Parren, P.M. Rudd,R.A. Dwek, D.R. Burton and I.A. Wilson. Contrasting IgG StructuresReveal Extreme Asymmetry and Flexibility. J. Mol. Biol., 319:9-18, 2002.

Schaller, M., D.R. Burton, H.J. Ditzel. Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. Nat. Immunol. 2:746-753, 2001.

Peretz, D., R.A. Williamson, K. Kaneko, J. Vergara, E. Leclerc, I.R. Mehlhorn, G. Legname, M.R. Wormald, P.M. Rudd, D.R. Burton and S.B. Prusiner. Antibodies inhibit prion propagation and promote clearance of infectivity from cell culture. Nature, 412:739-743, 2001.

Burton, D.R.   Antibodies in Viral Infection, Current Topics in Microbiology and Immunology Series, 2001.

Saphire, E.O., P.W.H.I. Parren, R. Pantophlet, M.B. Zwick, P. Rudd, R. Dwek, D.R. Burton and I. A. Wilson. Crystal structure of an intact human IgG with potent and broad activity against primary HIV-1 isolates: A template for HIV vaccine design. Science, 293:1155-1159, 2001.

Parren, P.W.H.I., P. Marx, A.J. Hessell, A. Luckay, J. Harouse, C. Cheng-Mayer, J.P. Moore and D.R. Burton. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virology, 75:8340-8347, 2001.

Moore, J.P., P.W.H.I. Parren, and D.R. Burton. Genetic subtypes, humoral immunity and HIV-1 vaccine development. J. Virology, 75:5721-5729, 2001.

Poignard, P., E. Ollmann Saphire, P.W.H.I. Parren and D.R. Burton. gp120: Biologic aspects of structural features, Annual Reviews of Immunology, 19: 253-274, 2001.

Parren, W.H.I, D.R. Burton, The anti-viral activity of antibodies in vitro and in vivo. Advances in Immunology, 77:195-262, 2001.

Zwick, M.B., A.F. Labrijn, M. Wang, C. Spenlehauer, E.O. Saphire, J.M. Binley, J.P. Moore, G.Stiegler, H. Katinger, D.R. Burton * and P.W.H.I. Parren*.   Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.   J. Virol., 75: 10892-10905, 2001.

Barbas, C.F. (III), D.R. Burton , J.K. Scott, G.J. Silverman.   Phage Display.   A Laboratory Manual , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001.

Burton, D.R., P.W.H.I. Parren. Fighting the Ebola virus, Nature, News and Views, 408:527-528, 2000.

Wang, H., M. N. Griffiths, D.R. Burton and P. Ghazal, Rapid antibody responses by low dose single-step dendritic cell-targeted immunization. Proc. Natl. Acad. Sci. USA, 96, 847-852, 2000.

Burton, D.R. and P.W.H.I. Parren, Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection? Nature Medicine, 6, 123-125, 2000.

Parren, P.W.H.I., P. Poignard, H.J. Ditzel, R.A. Williamson and D.R. Burton, Antibodies in human infectious disease. Immunologic Research, 21, 265-278, 2000.

Poignard, P., R. Sabbe, G.R. Picchio, M. Wang, R. J. Gulizia, H. Katinger, P.W.H.I. Parren, D.E. Mosier, D.R. Burton, Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo, Immunity, 10:1-20, 1999.

Williamson, R.A. D. Peretz, C. Pinilla, H. Ball, R. B. Bastidas, R. Rozenshteyn, R. A. Houghten, S. B. Prusiner and D. R. Burton. Mapping the prion protein using recombinant antibodies. J. Virol., 72: 9413-9418, 1998.

Burton, D.R.   Immunoglobulin, functions.   Encyclopedia of Immunology , Academic Press, (2 nd edition) P. J. Delves and I. M. Roitt, eds., pp. 1315-1319, 1998.

Parren, P.W.H.I., Q. J. Sattentau and D.R. Burton .   HIV-1 Antibody - debris or virion? Nat. Med. , 3 :366-367, 1997.

Burton, D.R. A vaccine for human immunodeficiency virus type1: The antibody perspective. Proc. Natl. Acad. Sci. USA, 94:10018-10023, 1997.

Burton, D.R. and D.C. Montefiori. The antibody response in HIV-1 infection. AIDS, 11(suppl A) S87-S98, 1997.

Parren, P.W.H.I., Q. J. Sattentau and D.R. Burton. HIV-1 Antibody - debris or virion? Nature Medicine, 3:366-367, 1997.

Binley, J.M., H.J. Ditzel, C.F. Barbas III, N. Sullivan, J. Sodroski, P.W.H.I. Parren and D.R. Burton. Human antibody responses to HIV-1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. AIDS Research and Human Retroviruses, 12:911-924, 1996.

Williamson, R.A., D. Peretz, N. Smorodinsky, R. Bastidas, T. Blochberger, A. Serban, S. DeArmond, S.B. Prusiner and D.R. Burton. Circumventing tolerance in order to generate autologous monoclonal antibodies to the prion protein. Proc. Natl. Acad. Sci. USA, 93:7279-7282, 1996.

Williamson, R.A. and D.R. Burton .   Combinatorial phage antibody libraries.   In: Molecular biology and biotechnology: A comprehensive desk reference , R.A. Myers, (ed.).   VCH Publishers, Germany, pp. 190-194, 1995.

Burton, D.R. Phage display. Immunotechnology, 1:87-94, 1995.

Sanna, P.P., R.A. Williamson, A. De Logu, F.E. Bloom and D.R. Burton. Directed selection of recombinant human monoclonal antibodies to HSV glycoproteins from phage display libraries. Proc. Natl. Acad. Sci. USA, 92:6439-6443, 1995.

Barbas, S.M., H.J. Ditzel, E.M. Salonen, W.P. Yang, G.J. Silverman and D.R. Burton. Human autoantibody recognition of DNA. Proc. Natl. Acad. Sci. USA, 92: 2529-2533, 1995.

Burton, D.R. * J. Pyati, R. Koduri, S.J. Sharp, G.B. Thornton, P.W.H.I. Parren, L.S.W. Sawyer, R.M. Hendry, N. Dunlop, P.L. Nara, M. Lamacchia, E. Garratty, E.R. Stiehm, Y.J. Bryson, Y. Cao, J.P. Moore, D.D. Ho and C.F. Barbas III*.   Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.   Science , 266 :1024-1027, 1994.

Burton, D.R. , and C.F. Barbas III.   Human antibodies from combinatorial libraries.   Adv. Immunol., 57 :191-280, 1994.

Burton, D.R.   The structure of immunoglobulins and their interaction with complement. In: Activators and Inhibitors of Complement , R.B. Sim (ed.).   The Netherlands: Kluwer Academic Publishers, pp. 17-36, 1993.

Burton, D.R. , and C.F. Barbas III.   Antibodies from libraries.   Nature , 359 :782-783, 1992.

Burton, D.R.   The conformation of antibodies.   In : Fc receptors and the action of antibodies , H. Metzger (ed.).   Washington, D.C.: American Society of Microbiology series, pp. 31-54, 1990.